Help me understand why you're voting no on the compensation
Help me understand why you're voting no on the compensation part of the ballot.
I'm a serious long with just under 1M shares and want CYDY and Leronlimab to progress to a much happier place. I voted all my shares "YES" on the different measures. I am not management but have been through similar wars with other struggling Biotechs.
This management group did not cause this FDA hold. They really currently have only 2 prime directives. 1)- keep the lights on and the door open 2) Get the hold lifted.
The lights will be kept open by issuing more shares- good.
Usually a Biotech company will tout and publicize whatever actions they are taking to advance their drugs to keep their shareholders informed. If management talked openly about the tit for tat with the FDA regarding the hold do you think the FDA would appreciate that? No, I don't either. So management keeps professionally quiet and does what the FDA is requiring of them to get the hold lifted. Meanwhile we are frustrated and are like the proverbial mushrooms except we're not fed very often..
This is like a whack-job surgeon has operated on you and made a real mess of things. So you fire that surgeon and get another surgeon to get you healthy again. Do you denigrate the second surgeon and threaten to pay him/her less because you are in a bad spot? No- you let surgeon #2 work to get you better even though you are in pain and not happy. Be pissed at surgeon #1 and the situation you're in but try to understand and support surgeon #2 to get your sorry ass back to health.
If you want to send a message to management I'd suggest using English and direct email or old fashioned USPS letters and being specific about your gripes.
I believe that the persisting hold is due to the FDA's making a point about how things are done in the Pharma world. When this management or any other management is in a similar situation and the FDA asks you to jump you don't just jump, you ask how high and how often....and then you wait.
I don't like this situation at all but waiting this out will be worth it because Leronlimab is a great drug with huge ramifications for health care.
18
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....
Continue Reading
A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...
Continue Reading
CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...
Continue Reading
PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...
Continue Reading
Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...
Continue Reading
An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...
Continue Reading
Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...
Continue Reading
The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...
Continue Reading
Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...
Continue Reading
University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...
Continue Reading
Top 5 Most Recently Viewed Articles
The cholesterol testing market witnessed massive growth starting back in 2024 when it was valued at USD 109.8 billion. By 2033, projections showed it skyrocketing to USD 247.5 billion as awareness around cardiovascular health started heating up. Market Drivers: Age and Awareness Surge As the years rolled on, more folks aged and with that came higher risks of heart...
Continue Reading
Elon Musk's Warning to American Airlines Elon Musk, the dynamic CEO of SpaceX, has voiced concerns regarding American Airlines Group Inc. (NASDAQ: AAL), stating that the airline could face significant customer loss if its in-flight internet service does not meet expectations. The Importance of Connectivity In response to a statement from Michael Nicolls, Starlink's VP of...
Continue Reading
Exciting Career Opportunities for Law Students Third-year and evening law students are invited to explore a unique opportunity designed to support and guide them into prestigious law firms and corporate legal departments. Legal Innovators is on the lookout for third-year law students and evening students for their innovative program. This program is tailored to assist...
Continue Reading
ALT5 Sigma Faces Major Governance Challenges Amid a turbulent period for ALT5 Sigma Corporation (NASDAQ: ALTS), significant concerns have emerged surrounding the company's governance practices and financial reporting. With the stock taking a steep nosedive of nearly 80%, the spotlight has turned to the internal operations of the firm, prompting investigations into...
Continue Reading
AI-Driven Growth in the Lignocellulosic Biofuel Market The global market for biofuels made from lignocellulosic feedstock is set for significant growth, with projections estimating an increase of USD 33.6 billion from 2024 to 2028. This exciting forecast, spurred on by breakthroughs in artificial intelligence (AI), suggests we are entering a new era for biofuels—one...
Continue Reading